Fresh Pathway Links Liver Congestion to Fibrosis and Cancer
Chronic liver congestion, a condition where blood pools in the liver, has long been associated with severe liver diseases like fibrosis, portal hypertension, and even cancer. Now, researchers at The University of Osaka have identified a specific molecular pathway that connects this congestion to these devastating outcomes, potentially opening new avenues for treatment.
Understanding Chronic Liver Congestion
Chronic liver congestion, also known as congestive hepatopathy, occurs when blood flow through the liver is persistently blocked or slowed. This can happen in various conditions, including congenital heart disease (particularly in patients who have undergone the Fontan procedure) and liver cirrhosis 1. Despite being a known risk factor for liver disease, the precise mechanisms linking congestion to fibrosis and cancer remained unclear until recently.
The Integrin αV-YAP-CTGF Pathway
The research, published in Gastroenterology, focuses on liver sinusoidal endothelial cells (LSECs), which line the liver’s tiny blood vessels and are directly impacted by changes in blood flow 4. Using advanced techniques like single-cell and spatial transcriptomics, the team analyzed liver samples from both a mouse model of congestion and patients with Fontan-associated liver disease.
Their findings revealed that increased hydrostatic pressure – similar to what occurs during chronic liver congestion – activates a signaling pathway involving integrin αV, Yes-associated protein (YAP), and connective tissue growth factor (CTGF) within the LSECs 2. Specifically, the activation of integrin αV triggers YAP, which in turn upregulates CTGF.
Implications for Treatment
Importantly, inhibiting integrin αV or blocking CTGF in LSECs improved outcomes in the mouse model of liver congestion 2. Further analysis of human liver samples confirmed the same pattern: YAP activation and increased CTGF levels were observed in LSECs from patients with chronic liver congestion.
“we discovered that a signaling pathway – the integrin αV-YAP-CTGF pathway – in specialized liver blood vessel cells appears to connect liver congestion to fibrosis,” explains Hayato Hikita, senior author of the study 2.
Future Directions
These findings suggest that targeting the integrin αV-YAP-CTGF pathway could offer a new therapeutic strategy for preventing or treating liver fibrosis, portal hypertension, and liver cancer in patients with chronic liver congestion. Because this pathway is also activated in liver cirrhosis caused by other conditions, the discoveries could have broader clinical benefits 3. Further research is needed to develop and test specific therapies that target this pathway.